Musculoskeletal Study Group

Program for Toronto 2008 Study Group Meeting


Wednesday, 7 May 2008, 19:30, Room 715 A/B


Why aren’t we there yet?
Evaluation of the (lack of) impact of MRI in OA:
Panel and audience discussion, and call for recommendations

In the late 1980s, the application of the superb soft tissue contrast of MRI to image the joint led to great optimism that inroads to understanding the natural history of, and applying therapeutics to, osteoarthritis would be quickly forthcoming. However, nearly 20 years later, much about clinical OA has yet to be discovered, there is yet to be a successful trial for a disease modifying OA drug (DMOAD), and radiography is still the mainstay of imaging of OA. The goal of the study group meeting is to delineate what has been accomplished in MRI of OA thus far, what impediments have been present, and provide recommendations for future directions.
19:30 Welcome
19:30 - 19:40 Review of MRI development for OA over the past 20 years
  Bernard Dardzinski, Ph.D., BRIE Franchise Imaging Lead, Blue Bell, PA, USA
19:40 – 19:50 How is MRI viewed by the OA clinical and pharmaceutical communities?
  Jeffrey Evelhoch, Amgen Inc., Thousand Oaks, CA, USA
19:50 - 20:10 Why have we not proven the utility of MRI for OA?
  Part I: Resource limitations
  Charles Mamisch, M.D., University of Bern, Bern, Switzerland
  Part II: Paradigm and existing dogma limitations
  Deborah Burstein, Ph.D., Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA, USA
20:10 - 20:20 The OAI: Current status of data acquisition and analysis
  Gayle Lester, Ph.D., NIAMS/NIH Bethesda, MD, USA
20:20 - 21:00 Recommendations for future success: (Panel and audience discussion)
  a. Delineation of concepts learned about OA from MRI data
b. Potential new areas in MRI for OA research
c. OAI: Potential data interpretation studies / additional acquisition protocols
d. Resources needed to accomplish the above
21:00 - 21:15 Administrative
  a. Election Results
b. Announcements